Stem cell transplant for high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a stem cell transplant from a donor can help children with high-risk neuroblastoma. It aims to replace damaged bone marrow with healthy cells to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or younger.
- You must have completed at least 7 rounds of chemotherapy and possibly surgery.
- Your cancer must have shrunk significantly or disappeared, and tests must show no remaining cancer cells.
- You must have completed radiation therapy to the main tumor or any spread areas before the transplant.
- Your major organs (heart, liver, lungs, kidneys) must be working well enough to handle the transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial is testing whether adding a vaccine to a substance called beta-glucan (which may help the immune system) and a growth factor drug called GM-CSF can help prevent high-risk neuroblastoma from coming back. You would receive these as an injection or IV. The study is for people whose cancer is in remission or has responded well to prior treatment.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.